For research use only. Not for therapeutic Use.
Risedronate, also known as NE-58095, often used as its sodium salt risedronate sodium (USAN), is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget/’s disease of bone.
| Catalog Number | I009046 |
| CAS Number | 115436-72-1 (sodium) |
| Synonyms | NE-58095; NE 58095; NE58095; Risedronate, Risedronic acid, Risedronate sodium, Actonel, Atelvia, Benet;sodium hydrogen (1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl)phosphonate |
| Molecular Formula | C7H10NNaO7P2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| InChI | InChI=1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1 |
| InChIKey | DRFDPXKCEWYIAW-UHFFFAOYSA-M |
| SMILES | OC(P(O)([O-])=O)(CC1=CC=CN=C1)P(O)(O)=O.[Na+] |
| Reference | </br>1:Biodegradable intranasal nanoparticulate drug delivery system of risedronate sodium for osteoporosis. Fazil M, Hassan MQ, Baboota S, Ali J.Drug Deliv. 2016 Sep;23(7):2428-2438. Epub 2015 Jan 27. PMID: 25625496 </br>2:Notice of Retraction: Sato Y, et al. Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke. Arch Intern Med. 2005;165(15):1743-1748. Bauchner H, Redberg RF.JAMA Intern Med. 2016 Sep 1;176(9):1256. doi: 10.1001/jamainternmed.2016.3771. No abstract available. PMID: 27258587 </br>3:Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. Kim JS, Jang SW, Son M, Kim BM, Kang MJ.Eur J Pharm Sci. 2016 Jan 20;82:45-51. doi: 10.1016/j.ejps.2015.11.011. Epub 2015 Dec 1. PMID: 26594027 </br>4:Comparative permeability studies with radioactive and nonradioactive risedronate sodium from self-microemulsifying drug delivery system and solution. Ilem-Ozdemir D, Gundogdu E, Ekinci M, Ozgenc E, Asikoglu M.Drug Dev Ind Pharm. 2015;41(9):1493-8. doi: 10.3109/03639045.2014.959022. Epub 2015 Jul 21. PMID: 25285358 </br>5:Immunomodulatory effect of bisphosphonate risedronate sodium on CD163+ arginase 1+ M2 macrophages: the development of a possible supportive therapy for angiosarcoma. Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Aiba S.Clin Dev Immunol. 2013;2013:325412. doi: 10.1155/2013/325412. Epub 2013 Dec 9. PMID: 24489574 Free PMC Article</br>6:Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers. Simanjuntak R, Setiawati E, Yunaidi DA, Handayani LR, Setiawati A, Utami BS, Rosa TA, Sholeh AB.Drug Res (Stuttg). 2014 Mar;64(3):136-40. doi: 10.1055/s-0033-1354365. Epub 2013 Sep 3. PMID: 24002927 </br>7:Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial. Cohran V, Cassedy A, Hawkins A, Bean J, Heubi J.J Pediatr Rehabil Med. 2013;6(2):85-93. doi: 10.3233/PRM-130242. PMID: 23803341 </br>8:Squamous metaplasia of the conjunctiva: a previously unrecognized adverse effect of risedronate sodium. Geneva II, Eagle RC, Barker-Griffith A, Stefanyszyn M, Weisenthal R.JAMA Ophthalmol. 2013 Feb;131(2):249-51. doi: 10.1001/jamaophthalmol.2013.578. No abstract available. PMID: 23411897 </br>9:Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal. Wang G, Zhu Z, Lei C, Li M, Liu F, Mao Y, Yu Z, Liu M, Zhao X, Tang T.J Int Med Res. 2012;40(5):1761-74. PMID: 23206458 </br>10:Hydrophilic versus hydrophobic porogens for engineering of poly(lactide-co-glycolide) microparticles containing risedronate sodium. Nasr M, Awad GA, Mansour S, Al Shamy A, Mortada ND.Pharm Dev Technol. 2013 Sep-Oct;18(5):1078-88. doi: 10.3109/10837450.2012.693507. Epub 2012 Jun 2. PMID: 22656315 |
